Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Ivana Magovcevic-Liebisch Acquires 5,000 Shares

Vigil Neuroscience, Inc. (NASDAQ:VIGL) CEO Ivana Magovcevic-Liebisch acquired 5,000 shares of the stock in a transaction dated Thursday, December 5th. The shares were bought at an average cost of $2.34 per share, with a total value of $11,700.00. Following the transaction, the chief executive officer now directly owns 212,687 shares of the company’s stock, valued at $497,687.58. This represents a 2.41 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Vigil Neuroscience Stock Up 2.2 %

Shares of NASDAQ VIGL traded up $0.05 during mid-day trading on Thursday, reaching $2.31. 402,251 shares of the company were exchanged, compared to its average volume of 237,699. The company’s 50-day simple moving average is $3.35 and its 200-day simple moving average is $3.61. The stock has a market capitalization of $94.43 million, a P/E ratio of -1.10 and a beta of 1.65. Vigil Neuroscience, Inc. has a twelve month low of $2.08 and a twelve month high of $6.06.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new stake in Vigil Neuroscience in the 2nd quarter worth about $26,000. Renaissance Technologies LLC raised its stake in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vigil Neuroscience in the 2nd quarter worth about $87,000. Geode Capital Management LLC raised its stake in Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after purchasing an additional 66,712 shares in the last quarter. Finally, Walleye Capital LLC raised its stake in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on VIGL. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. William Blair began coverage on shares of Vigil Neuroscience in a research report on Wednesday. They issued an “outperform” rating for the company. Wedbush raised their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday, November 8th. Finally, Guggenheim decreased their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.